Deletion of the der(9q) in chronic myeloid leukemia: The controversy continues

Leukemia and Lymphoma

Volumn 50, Issue 6, 2009, Pages 871-872

  Godley, Lucy A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB; MICRORNA; PROTEIN TYROSINE KINASE INHIBITOR;

CELL PROLIFERATION; CHROMOSOME 9Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; NOTE; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RNA DEGRADATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; FUSION PROTEINS, BCR-ABL; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES; RISK FACTORS; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 68449089452     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190902980889     Document Type: Note

References (11)

1. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: Expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001;128:114-119.
2. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-1738.
3. Pieńkowska-Grela B, Rygier J, Woroniecka R, Grygalewicz B, Pastwińska A, Krawczyk P, et al. Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib. Leuk Lymphoma 2009;50:952-965.
4. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281-2286.
5. Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, et al. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. Cancer 2008;113:772-781.
6. Huntly BJ, Guilhot F, Reid AG, Vassiliou G, Hennig E, Franke C, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205-2212.
7. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95: 738-743.
8. Storlazzi CT, Specchia G, Anelli L, Albano F, Pastore D, Zagaria A, et al. Breakpoint characterization of der(9) deletions in chronic myeloid leukemia patients. Genes Chromosomes Cancer 2002;35:271-276.
9. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: Deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-1168.
10. Chaubey A, Karanti S, Rai D, Oh T, Adhvaryu SG, Aguiar RC. MicroRNAs and deletion of the derivative chromosome 9 in chronic myeloid leukemia. Leukemia 2009;23:186-188.
11. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417.